Liver cancer detection is automated

Share This Post

CT scan (Computed Tomography) is basically an X-ray image, which can be used to provide clinicians with a detailed view of our internal organs, and can usually diagnose various forms of cancer. Previously, the use of CT to diagnose liver cancer was hindered to some extent by changes in the shape and structure of individual livers and the similarity of tissues in adjacent organs in CT images.

Amita Das of the Technical Education and Research Institute of the Department of Electronic and Communication Engineering at Siksha’O’Anusandhan University in Orissa, as well as Electrical Engineering at SCB Medical School and DY Patil Ramrao Adik Institute of Technology in Nerul, New Mumbai The department has developed a new texture analysis technology based on adaptive fuzzy clustering, which can be used to classify abdominal CT scans to diagnose liver cancer. This method is based on the extracted texture, morphology, and statistical features from the scan and using them as input, which can judge the neural network classifier to distinguish between benign and malignant liver tumors.

Today, they tested their method with a series of 45 images and studied sensitivity, specificity, and accuracy. The team was able to achieve nearly 99% accuracy in detecting tumors, and this result is already very good. The researchers’ next plan is to provide more data and training for the system, thereby further improving the reliability of the technology and developing an automatic diagnostic method that does not have the possibility of human error.

https://medicalxpress.com/news/2018-10-automated-liver-cancer.html

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy